Target |
Mechanism CD19 modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NY-ESO-1 inhibitors [+2] |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date30 Jun 2017 |
Sponsor / Collaborator |
Start Date15 Jan 2016 |
Sponsor / Collaborator |
Start Date01 Apr 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Anti-CD19 CAR T-cell therapy(Shenzhen Institute For Innovation & Translational Medicine) ( CD19 ) | Chronic Lymphocytic Leukemia More | Pending |
Anti-NY ESO-1 TCR-transduced T cells(Shenzhen Institute For Innovation & Translational Medicine) ( NY-ESO-1 ) | Ovarian Cancer More | Pending |